- Home
- WLGS vs CVKD Comparison
WLGS vs CVKD Comparison
Compare WLGS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- CVKD
- Stock Information
- Founded
- WLGS 1981
- CVKD 2022
- Country
- WLGS Hong Kong
- CVKD United States
- Employees
- WLGS N/A
- CVKD N/A
- Industry
- WLGS Engineering & Construction
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- WLGS Consumer Discretionary
- CVKD Health Care
- Exchange
- WLGS Nasdaq
- CVKD Nasdaq
- Market Cap
- WLGS 4.4M
- CVKD 29.5M
- IPO Year
- WLGS 2023
- CVKD 2023
- Fundamental
- Price
- WLGS $0.04
- CVKD $12.80
- Analyst Decision
- WLGS
- CVKD Strong Buy
- Analyst Count
- WLGS 0
- CVKD 1
- Target Price
- WLGS N/A
- CVKD $32.00
- AVG Volume (30 Days)
- WLGS 47.9M
- CVKD 32.3K
- Earning Date
- WLGS 08-14-2025
- CVKD 08-06-2025
- Dividend Yield
- WLGS N/A
- CVKD N/A
- EPS Growth
- WLGS N/A
- CVKD N/A
- EPS
- WLGS N/A
- CVKD N/A
- Revenue
- WLGS $3,951,649.00
- CVKD N/A
- Revenue This Year
- WLGS N/A
- CVKD N/A
- Revenue Next Year
- WLGS N/A
- CVKD N/A
- P/E Ratio
- WLGS N/A
- CVKD N/A
- Revenue Growth
- WLGS N/A
- CVKD N/A
- 52 Week Low
- WLGS $0.03
- CVKD $5.70
- 52 Week High
- WLGS $9.66
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- WLGS 26.31
- CVKD 49.60
- Support Level
- WLGS $0.03
- CVKD $11.00
- Resistance Level
- WLGS $0.05
- CVKD $13.71
- Average True Range (ATR)
- WLGS 0.01
- CVKD 1.14
- MACD
- WLGS 0.01
- CVKD 0.10
- Stochastic Oscillator
- WLGS 21.43
- CVKD 63.54
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED. WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, water supply and sewage disposal systems, and site project management.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.